Pharmaceutical companyLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field. in FranceLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field., part of Sanofi. FDA records under 2 spellings of its name, each linked to the record. See the Sanofi group view.
As of Nov 16, 2026, FDA's public records list Sanofi-Synthelabo with 2 drug applications and 1 drug recall. The most recent is a drug recall dated Feb 26, 2013: Rifadin (rifampin) capsules, USP, 150 mg, 100-count capsules per bottle, Manufactured by….
Drug approvals, 510(k) clearances, recalls and letters, 2017 to 2026 to date
A hatched bar is a year that is not over, so its count covers only part of the year.
| Date | Record | Source |
|---|---|---|
| Feb 26, 2013 | Rifadin (rifampin) capsules, USP, 150 mg, 100-count capsules per bottle, Manufactured by: Fabrique par Sanofi-Aventis Canada Inc., Laval, QuClass II · Subpotent Drug: During review of retain samples, the manufacturer observed low fill in some capsules, which was related | Drug recalls |
Spellings are joined only when they reduce to the same name, or a reviewed source names the same company. Sharing an FDA establishment number (FEI) is not enough: contract sites make products for many firms. Facts marked AI were labelled by a language model from the firm's FDA names; everything else comes from FDA or Wikidata. How this page is built